Low-dose aspirin affects the clinicopathological features of gastric cancer

Jin Hwang Hye, Hoon Youn Young, Jie-Hyun Kim, Bock Chung Jae, Yongchan Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: There have been investigations on the chemopreventive effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in gastric cancer and also on the association between cyclo-oxygenase 2 expression and the clinicopathological features of gastric cancer. However, it is not yet clear whether the cardioprotective properties of low-dose aspirin could affect the biological behavior of gastric cancer. This study was aimed at investigating the association between the use of low-dose aspirin and clinicopathological features of gastric cancer in human. Method: A case-control study was performed retrospectively by comparing the clinicopathological parameters between two groups of gastric cancers, 47 (30.5%) low-dose aspirin users and 107 (69.5%) non-aspirin users who were diagnosed and underwent operation for gastric cancers. Results: The gastric cancers of aspirin user group showed favorable clinicopathological features, such as earlier tumor stage (overall stage, T and N stage: p <0.001, <0.001, and 0.002, respectively), smaller size (p = 0.03), and intestinal type rather than diffuse type (p = 0.004). But these differences were significant only in non-cardiac cancer while cardiac cancer patients showed no significant association with low-dose aspirin usage (overall stage, T stage, N stage, tumor size, and histological type: p <0.001, <0.001, 0.003, 0.035, and 0.004, respectively, by Cochran-Mantel-Haenszel statistics). Conclusion: The use of low-dose aspirin might affect the clinicopathological features in gastric cancers, and possibly have a favorable protective effect on the progression of gastric cancer in a subset of non-cardiac gastric cancer patients.

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalDigestion
Volume73
Issue number1
DOIs
Publication statusPublished - 2006 Apr 1

Fingerprint

Aspirin
Stomach Neoplasms
Neoplasms
Heart Neoplasms
Prostaglandin-Endoperoxide Synthases
Case-Control Studies
Anti-Inflammatory Agents
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Hye, Jin Hwang ; Young, Hoon Youn ; Kim, Jie-Hyun ; Jae, Bock Chung ; Lee, Yongchan. / Low-dose aspirin affects the clinicopathological features of gastric cancer. In: Digestion. 2006 ; Vol. 73, No. 1. pp. 54-59.
@article{b5e5534e86484a9689699c4848a1e22b,
title = "Low-dose aspirin affects the clinicopathological features of gastric cancer",
abstract = "Background/Aims: There have been investigations on the chemopreventive effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in gastric cancer and also on the association between cyclo-oxygenase 2 expression and the clinicopathological features of gastric cancer. However, it is not yet clear whether the cardioprotective properties of low-dose aspirin could affect the biological behavior of gastric cancer. This study was aimed at investigating the association between the use of low-dose aspirin and clinicopathological features of gastric cancer in human. Method: A case-control study was performed retrospectively by comparing the clinicopathological parameters between two groups of gastric cancers, 47 (30.5{\%}) low-dose aspirin users and 107 (69.5{\%}) non-aspirin users who were diagnosed and underwent operation for gastric cancers. Results: The gastric cancers of aspirin user group showed favorable clinicopathological features, such as earlier tumor stage (overall stage, T and N stage: p <0.001, <0.001, and 0.002, respectively), smaller size (p = 0.03), and intestinal type rather than diffuse type (p = 0.004). But these differences were significant only in non-cardiac cancer while cardiac cancer patients showed no significant association with low-dose aspirin usage (overall stage, T stage, N stage, tumor size, and histological type: p <0.001, <0.001, 0.003, 0.035, and 0.004, respectively, by Cochran-Mantel-Haenszel statistics). Conclusion: The use of low-dose aspirin might affect the clinicopathological features in gastric cancers, and possibly have a favorable protective effect on the progression of gastric cancer in a subset of non-cardiac gastric cancer patients.",
author = "Hye, {Jin Hwang} and Young, {Hoon Youn} and Jie-Hyun Kim and Jae, {Bock Chung} and Yongchan Lee",
year = "2006",
month = "4",
day = "1",
doi = "10.1159/000092248",
language = "English",
volume = "73",
pages = "54--59",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "1",

}

Low-dose aspirin affects the clinicopathological features of gastric cancer. / Hye, Jin Hwang; Young, Hoon Youn; Kim, Jie-Hyun; Jae, Bock Chung; Lee, Yongchan.

In: Digestion, Vol. 73, No. 1, 01.04.2006, p. 54-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low-dose aspirin affects the clinicopathological features of gastric cancer

AU - Hye, Jin Hwang

AU - Young, Hoon Youn

AU - Kim, Jie-Hyun

AU - Jae, Bock Chung

AU - Lee, Yongchan

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background/Aims: There have been investigations on the chemopreventive effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in gastric cancer and also on the association between cyclo-oxygenase 2 expression and the clinicopathological features of gastric cancer. However, it is not yet clear whether the cardioprotective properties of low-dose aspirin could affect the biological behavior of gastric cancer. This study was aimed at investigating the association between the use of low-dose aspirin and clinicopathological features of gastric cancer in human. Method: A case-control study was performed retrospectively by comparing the clinicopathological parameters between two groups of gastric cancers, 47 (30.5%) low-dose aspirin users and 107 (69.5%) non-aspirin users who were diagnosed and underwent operation for gastric cancers. Results: The gastric cancers of aspirin user group showed favorable clinicopathological features, such as earlier tumor stage (overall stage, T and N stage: p <0.001, <0.001, and 0.002, respectively), smaller size (p = 0.03), and intestinal type rather than diffuse type (p = 0.004). But these differences were significant only in non-cardiac cancer while cardiac cancer patients showed no significant association with low-dose aspirin usage (overall stage, T stage, N stage, tumor size, and histological type: p <0.001, <0.001, 0.003, 0.035, and 0.004, respectively, by Cochran-Mantel-Haenszel statistics). Conclusion: The use of low-dose aspirin might affect the clinicopathological features in gastric cancers, and possibly have a favorable protective effect on the progression of gastric cancer in a subset of non-cardiac gastric cancer patients.

AB - Background/Aims: There have been investigations on the chemopreventive effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in gastric cancer and also on the association between cyclo-oxygenase 2 expression and the clinicopathological features of gastric cancer. However, it is not yet clear whether the cardioprotective properties of low-dose aspirin could affect the biological behavior of gastric cancer. This study was aimed at investigating the association between the use of low-dose aspirin and clinicopathological features of gastric cancer in human. Method: A case-control study was performed retrospectively by comparing the clinicopathological parameters between two groups of gastric cancers, 47 (30.5%) low-dose aspirin users and 107 (69.5%) non-aspirin users who were diagnosed and underwent operation for gastric cancers. Results: The gastric cancers of aspirin user group showed favorable clinicopathological features, such as earlier tumor stage (overall stage, T and N stage: p <0.001, <0.001, and 0.002, respectively), smaller size (p = 0.03), and intestinal type rather than diffuse type (p = 0.004). But these differences were significant only in non-cardiac cancer while cardiac cancer patients showed no significant association with low-dose aspirin usage (overall stage, T stage, N stage, tumor size, and histological type: p <0.001, <0.001, 0.003, 0.035, and 0.004, respectively, by Cochran-Mantel-Haenszel statistics). Conclusion: The use of low-dose aspirin might affect the clinicopathological features in gastric cancers, and possibly have a favorable protective effect on the progression of gastric cancer in a subset of non-cardiac gastric cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=33744455716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744455716&partnerID=8YFLogxK

U2 - 10.1159/000092248

DO - 10.1159/000092248

M3 - Article

C2 - 16554658

AN - SCOPUS:33744455716

VL - 73

SP - 54

EP - 59

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -